Yungjin Pharm Co Ltd (003520) - Total Assets
Based on the latest financial reports, Yungjin Pharm Co Ltd (003520) holds total assets worth ₩246.25 Billion KRW (≈ $166.88 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 003520 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Yungjin Pharm Co Ltd - Total Assets Trend (2013–2024)
This chart illustrates how Yungjin Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. See 003520 net assets for net asset value and shareholders' equity analysis.
Yungjin Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Yungjin Pharm Co Ltd's total assets of ₩246.25 Billion consist of 52.9% current assets and 47.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 1.5% |
| Accounts Receivable | ₩46.02 Billion | 19.7% |
| Inventory | ₩70.94 Billion | 30.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.68 Billion | 0.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Yungjin Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Yungjin Pharm Co Ltd (003520) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yungjin Pharm Co Ltd's current assets represent 52.9% of total assets in 2024, an increase from 49.3% in 2013.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2024, down from 5.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 30.3% of total assets.
Yungjin Pharm Co Ltd Competitors by Total Assets
Key competitors of Yungjin Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Suven Pharmaceuticals Limited
NSE:SUVENPHAR
|
India | Rs30.32 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
Bausch Health Companies Inc
TO:BHC
|
Canada | CA$24.50 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Shandong Lukang Pharmaceutical Co Ltd
SHG:600789
|
China | CN¥9.88 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥11.80 Billion |
Yungjin Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 1.47 | 3.27 |
| Quick Ratio | 0.58 | 0.71 | 1.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩21.13 Billion | ₩41.29 Billion | ₩68.53 Billion |
Yungjin Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Yungjin Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.81 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 3.4% |
| Total Assets | ₩234.26 Billion |
| Market Capitalization | $152.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Yungjin Pharm Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Yungjin Pharm Co Ltd's assets grew by 3.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Yungjin Pharm Co Ltd (2013–2024)
The table below shows the annual total assets of Yungjin Pharm Co Ltd from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩234.26 Billion ≈ $158.75 Million |
+3.38% |
| 2023-12-31 | ₩226.60 Billion ≈ $153.56 Million |
+11.58% |
| 2022-12-31 | ₩203.08 Billion ≈ $137.63 Million |
+4.63% |
| 2021-12-31 | ₩194.10 Billion ≈ $131.54 Million |
+3.19% |
| 2020-12-31 | ₩188.10 Billion ≈ $127.47 Million |
-6.16% |
| 2019-12-31 | ₩200.45 Billion ≈ $135.84 Million |
+2.21% |
| 2018-12-31 | ₩196.11 Billion ≈ $132.90 Million |
-3.79% |
| 2017-12-31 | ₩203.85 Billion ≈ $138.14 Million |
+2.25% |
| 2016-12-31 | ₩199.35 Billion ≈ $135.10 Million |
+2.92% |
| 2015-12-31 | ₩193.70 Billion ≈ $131.26 Million |
+8.23% |
| 2014-12-31 | ₩178.97 Billion ≈ $121.28 Million |
+5.69% |
| 2013-12-31 | ₩169.33 Billion ≈ $114.76 Million |
-- |
About Yungjin Pharm Co Ltd
Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea and internationally. The company offers cephalosporin antibiotic, antipsychotic, cardiovascular, gastrointestinal, metabolic, neuropsychiatry, respiratory, infectious, anti-inflammatory and analgesics, nutritional supplement, and urology products. It also provides vitamins, minerals, and other products; and APIs. The com… Read more